Only five patients with thyroid carcinoma were included in an integrated analysis of three ongoing early-phase trials [59] in metastatic or locally advanced solid tumors harboring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated with entrectinib. Here, NTRK1 is linked to thyroid gland carcinoma.